Submit Content
Get the latest delivered to your inbox
Privacy Policy

Alkermes

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

    Collaborative and Risk-focused Engagement (CaRE™) at Alkermes Image

    POSTED 

    05-07-20

    Collaborative and Risk-focused Engagement (CaRE™) at Alkermes

    In 2018, we significantly enhanced CaRE™, our proprietary risk mitigation program designed to encourage employees to preemptively identify and address EHSS risks and enhance sustainability.
    Statement from Alkermes on Response to COVID-19 Image

    POSTED 

    05-04-20

    Statement from Alkermes on Response to COVID-19

    Originally posted by Alkermes

    At Alkermes, we are closely monitoring and rapidly responding to the impact of COVID-19 on our employees...

    Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities Image

    POSTED 

    05-04-20

    Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities

     Alkermes plc (Nasdaq: ALKS) today announced that the company is now accepting applications for its newly-established COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program. The...

    Alkermes logo

    Alkermes

    Alkermes

    Join today and get the latest delivered to your inbox